Evotec Se (EVO) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Competitors, else..
 
Evotec Se  (NASDAQ: EVO)
 

Evotec Se Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EVO Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q4 MRQ) -1.08 % 7.99 % 8.07 % 9.17 %
Q / Q Revenue Growth (Q4 MRQ) - 1.44 % 1.81 % 4.22 %
Y / Y Revenue Growth (for 12 months ending Q4 TTM) -1.08 % 7.47 % 7.04 % %
Sequential Revenue Growth (for 12 months ending Q4 TTM) - 4.22 % 3.51 % 2.08 %
Revenue 5 Year Average Growth - 7.41 % 8.65 % 10.59 %


EVO's Growth Comparisons in IV. Quarter 2025




Although the Major Pharmaceutical Preparations industry saw advancing Revenue by 7.99%, Evotec Se announced -1.08% year on year sales decline in the fourth quarter 2025, to $ 883 millions, and underperformed the 8.07% Revenue growth in the Healthcare sector. Weak fourth quarter sales, in Major Pharmaceutical Preparations industry and within the Healthcare sector, were reflected in Evotec Se results which underperformed overall market.

Sequentially company's Revenue were unchanged from the third quarter results. . Looking into annual growth, sales grew by % on average in last five years, while S & P 500's including only Businesses with the fourth quarter 2025 earnings reports, average yearly sales growth is 10.59%.

EVO Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Discovery Preclinical Development
-
-
Just - Evotec Biologics
-
-
Intereliminations
-
-
Intereliminations Discovery Preclinical Development
-
-
Intereliminations Just - Evotec Biologics
-
-
USA
-
-
USA Discovery Preclinical Development
-
-
USA Just - Evotec Biologics
-
-
Germany
-
-
Germany Discovery Preclinical Development
-
-
France
-
-
France Discovery Preclinical Development
-
-
France Just - Evotec Biologics
-
-
United Kingdom
-
-
United Kingdom Discovery Preclinical Development
-
-
Switzerland
-
-
Switzerland Discovery Preclinical Development
-
-
Switzerland Just - Evotec Biologics
-
-
Rest of the world
-
-
Rest of the world Discovery Preclinical Development
-
-
Rest of the world Just - Evotec Biologics
-
-
At a point in time
-
-
Over a period of time
-
-
Fee for service and FTE-based research services
-
-
Material re-charges to customers
-
-
Milestone fees
-
-
Licences
-
-
Other fees
-
-
Discovery Preclinical Development At a point in time
-
-
Discovery Preclinical Development Over a period of time
-
-
Discovery Preclinical Development Fee for service and FTE-based research services
-
-
Discovery Preclinical Development Material re-charges to customers
-
-
Discovery Preclinical Development Milestone fees
-
-
Discovery Preclinical Development Licences
-
-
Discovery Preclinical Development Other fees
-
-
Just - Evotec Biologics At a point in time
-
-
Just - Evotec Biologics Over a period of time
-
-
Just - Evotec Biologics Fee for service and FTE-based research services
-
-
Just - Evotec Biologics Licences
-
-
Major customers
-
-
Major customers Just - Evotec Biologics
-
-
Major customers Discovery Preclinical Development
-
-
Total
-
-


Growth Rates of EVO's Income in the fourth quarter 2025


EVO Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q4 MRQ) - 53.67 % 27.58 % 29.95 %
Sequential Operating Income Change (Q4 MRQ) - -27.23 % -17.34 % 4.5 %
Y / Y Operating Income Growth (Q4 TTM) - 48 % 37.03 % 14.37 %
Sequential Operating Income Growth (Q4 TTM) - 13.44 % 9.74 % 6.96 %
Operating Income 5 Year Avg. Change - 14.39 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q4 MRQ) - - - 21.83 %
Sequential Income from Cont. Ops. Change (Q4 MRQ) - - - 11.13 %
Y / Y Income from Cont. Ops. Change (Q4 TTM) - -59.4 % -25.13 % 16.46 %
Sequential Income from Cont. Ops. Change (Q4 TTM) - -10.61 % -6.43 % 6.05 %
Income from Cont. Ops. 5 Year Avg. Change - -0.55 % 0.17 % -28.52 %

EVO Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q4 MRQ) - -26.27 % 16.75 % 21.56 %
Q / Q Net Income Growth (Q4 MRQ) - -43.4 % -34.6 % 11.12 %
Y / Y Net Income Change (Q4 TTM) - 27.23 % 32.74 % 16.59 %
Sequential Net Income Change (Q4 TTM) - 3.41 % 7.31 % 6.03 %
Net Income 5 Year Avg. Growth - 14.55 % 9.21 % 22.96 %

EVO's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q4 MRQ) - - - 21.83 %
Sequential EPS from Cont. Ops. Change (Q4 MRQ) - - - 11.13 %
Y / Y EPS from Cont. Ops. Change (Q4 TTM) - - - -
Sequential EPS from Cont. Ops. Change (Q4 TTM) - - - -99.7 %
EPS from Cont. Ops. 5 Year Avg. Growth - -10.79 % 0.17 % -28.52 %



EVO EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q4 MRQ) - -29.53 % 16.75 % -28.52 %
Q / Q EPS Net Growth (Q4 MRQ) - -32.44 % -34.6 % 11.12 %
Y / Y EPS Net Change (for 12 months ending Q4 TTM) - - - -99.97 %
Sequential EPS Net Change (for 12 months ending Q4 TTM) - - - -99.87 %
EPS Net 5 Year Avg. Change - 14.55 % 9.21 % 22.96 %



Evotec Se reported bottom-line of $ 0.00 in the fourth quarter, compare to $ 0.00 in the same quarter a year ago. Major Pharmaceutical Preparations industry fell by -29.53%, while Healthcare sector increased by 16.75%, and overall market improved by 21.56%.

Sequentially company's EPS were unchanged from the third quarter results. . Looking into annual growth, income per share grew by % on average in the last five years, while the S & P 500's including only the businesses with the fourth quarter 2025 financial results, average yearly income per share growth is 22.96%.

EVO Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q4 MRQ) - -15.03 % -10.43 % 2 %
Sequential Free Cash Flow Change (Q4 MRQ) - -44.18 % -28.82 % 22.32 %
Y / Y Free Cash Flow Change (Q4 TTM) - 9.6 % 11.09 % 11.81 %
Sequential Free Cash Flow Change (Q4 TTM) - 1.75 % 1.93 % 2.41 %
Free Cash Flow 5 Year Avg. Change - 1.86 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q4 MRQ) - - -90.24 % 1035.72 %
Sequential Net Cash Flow Change (Q4 MRQ) - - -99.01 % -
Y / Y Net Cash Flow Change (Q4 TTM) - -21.47 % -23.28 % -
Sequential Net Cash Flow Change (Q4 TTM) - -44.21 % -25.11 % -
Net Cash Flow 5 Year Avg. Change - 29.88 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q4 MRQ) -38.25 % 19.29 % 9.45 % 23.41 %
Sequential Capital Expenditures Change (Q4 MRQ) - 20.61 % 18.78 % 18.97 %
Y / Y Capital Expenditures Change (Q4 TTM) -38.25 % 20.54 % 10.57 % 23.88 %
Sequential Capital Expenditures Change (Q4 TTM) -38.25 % 11.3 % 6.56 % 7.02 %
Capital Expenditures 5 Year Avg. Change - 8.94 % 9.18 % 14.72 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.